27 February 2015 – Maternal health, wellbeing and survival must remain a central goal and an investment priority in the post-2015 framework for sustainable development to ensure that progress continues and accelerates, with a focus on reducing inequities and discrimination. Attention to maternal mortality and morbidity must be accompanied by improvements along the continuum of care for women and children, including commitments to sexual and reproductive health and newborn and child survival.
WHO and its partners around the world issued a statement on the prevention and elimination of disrespect and abuse during facility-based delivery. Every woman has the right to the highest attainable standard of health, including the right to dignified, respectful care during pregnancy and childbirth. However, across the world many women experience disrespectful, abusive, or neglectful treatment during childbirth in facilities. These practices can violate women’s rights, deter women from seeking and using maternal health care services and can have implications for their health and well-being.
A new World Health Organization study reveals that only half of women who gave birth preterm in hospitals have received steroid injections which prevent death and disability among vulnerable, preterm newborns. The study is the largest to look at the use of these life-saving drugs internationally. These drugs have existed for decades, don’t require refrigeration, and cost less than US$ 1 an injection.
Tetanus Toxoid vaccine
WHO is concerned that misinformation circulating in the media about the Tetanus Toxoid vaccine could have a seriously negative impact on the health of women and children. The Organization confirms that the Tetanus Toxoid (TT) vaccine is safe. The vaccine has been used in 52 countries, to immunize 130 million women to protect them and their newborn babies from tetanus. There is no HCG hormone in tetanus toxoid vaccines.
The EPMM Working Group invited comments on the draft paper "Strategies toward ending preventable maternal mortality". A country (Member States) and public consultation was conducted during August 2014. The next step consists in reviewing and incorporating the received comments and suggestion into the Strategy.
Study on fistula repair surgery
A vaginal fistula is a devastating condition, affecting an estimated 2 million girls and women across Africa and Asia. There are numerous challenges associated with providing fistula repair services in developing countries. Finding ways of providing services in a more efficient and cost-effective manner, without compromising surgical outcomes and the overall health of the patient, is paramount. WHO has embraced this challenge and taken leadership to expand necessary research to improve the lives of women affected by fistula.
Preventing postpartum haemorrhage
WHO, Merck and Ferring Pharmaceuticals announce a partnership to evaluate a new, proprietary, room-temperature stable formulation of carbetocin—a drug for preventing postpartum haemorrhage after childbirth.This trial is a new step for WHO. If the trial is successful, it could mean the difference between life and death for thousands of women.